| Name | Title | Contact Details |
|---|
A Systematic Approach To Extractables And Leachables: A Review Of Guidance From The Industry
Social Media Commenting Policy Welcome! Whitman-Walker maintains social media channels as a service to our supporters who wish to keep updated on news from WWH and possibly share information with one another. We are glad to have you join us! We ...
Respira Therapeutics, Inc., founded in 2010 with offices in Albuquerque, New Mexico, is a development stage inhaled pharmaceutical development company focused on commercializing its "best in class", high efficiency AOS-DPI, dry powder inhaler (DPI) drug delivery technology to deliver RT234, a proprietary inhaled formulation of an off patent oral drug via the lung to treatment of multiple orphan indications in the fields of pulmonary hypertension and other diseases. Investors in Respira include Cottonwood Technology Fund and Sun Mountain Capital and individual investors. To date Respira has performed extensive testing demonstrating its advanced AOS-DPI prototypes can deliver 2-3X more drug to the lung than commercially available DPI technologies. Respira is planning proof of concept clinical trials of an inhaled formulation of RT234 in pulmonary arterial hypertension patients in the near future.
World-Leading Biodefense Indoor Air Protection Systemâ„¢ Scientifically proven to destroy COVID-19 (99.999%) and Anthrax spores (99.98%) instantaneously in a single pass. Learn More Scientifically proven to Kill Sars-CoV-2, the virus that causes COVID-19...
Find the most effective and affordable therapy, counseling, and treatments with Foresight! With our advanced technology, we make sure to provide the most effective and accurate treatment to our patients. We accept most insurances, so book today and sta...